Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nuclear Medicine Review
MENU
Shortcuts Submit an article Author Guidelines Editorial Board Reviewers 2023

open access

Vol 25, No 1 (2022)
Research paper
Submitted: 2021-08-04
Accepted: 2021-11-30
Published online: 2022-01-26
View PDF Download PDF file
Get Citation

Detection of a second primary cancer in a 18F-fluorocholine PET/CT – multicentre retrospective analysis on a group of 1345 prostate cancer patients

Paulina Cegla1, Katarzyna Scibisz-Dziedzic2, Kamila Witkowska3, Anna Kubiak4, Ewa Wierzchoslawska56, Witold Kycler78, Beata Chrapko2, Rafał Czepczyński39
DOI: 10.5603/NMR.a2022.0006
·
Pubmed: 35137934
·
Nucl. Med. Rev 2022;25(1):25-30.
Affiliations
  1. Department of Nuclear Medicine, Greater Poland Cancer Center, Poznan, Poland
  2. Chair and Department of Nuclear Medicine, Medical University of Lublin, Lublin, Poland
  3. Department of Nuclear Medicine, Affidea Poznan, Poland
  4. Greater Poland Cancer Registry, Greater Poland Cancer Centre, Poznan, Poland
  5. Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland
  6. Radiology Department, Greater Poland Cancer Centre, Poznan, Poznań, Poland
  7. Gastrointestinal Surgical Oncology Department, Greater Poland Cancer Centre, Poznan, Poland
  8. Department of Head and Neck Surgery, Poznan University of Medical Sciences, Poznan, Poland
  9. Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland

open access

Vol 25, No 1 (2022)
Original articles
Submitted: 2021-08-04
Accepted: 2021-11-30
Published online: 2022-01-26

Abstract

Background: Aim of this study was to evaluate the rate of incidental detection of second primary cancer (SPC) at 18F-fluorocholine ([18F]FCH) positron emission tomography/computed tomography (PET/CT) performed in prostate cancer patients. Material and methods: A retrospective analysis was performed on a group of 1345 prostate cancer patients, who underwent [18F]FCH PET/CT study because of suspicion of recurrence (n = 937) or for initial staging (n = 408). Images were acquired after intravenous injection [18F]FCH with a mean activity of 200 ± 75 MBq (5.4 ± 2 mCi), from the top of the head to the half of the thigh. The confirmation of second primary cancer was obtained from the cancer registry. Results: Based on the [18F]FCH PET/CT scans, a second primary cancer was suspected in 89 patients (6.6%). Of these, a malignancy was histologically confirmed in 26 patients (29% of all suspected findings and 1.9% of the complete cohort). Lung cancer (including adenocarcinoma, neuroendocrine cancer) was diagnosed in 13 patients (50%) and hematologic neoplasm (including chronic lymphocytic leukemia, Hodgkin lymphoma, follicular lymphoma, and multiple myeloma) in 5 patients (19%). 18F-fluorocholine PET/CT also revealed esophageal cancer, mesothelioma, testicular, renal, bladder, and colorectal cancer inindividual patients, non-keratinizing squamous cell carcinoma (SCC) of the skin as well as head and neck SCC with unknown primary. Conclusion: We conclude that incidental detection of a second primary cancer in prostate cancer patients using [18F]FCH PET/CT is not very common and that lung cancer and hematologic malignancies are most frequently detected.

Abstract

Background: Aim of this study was to evaluate the rate of incidental detection of second primary cancer (SPC) at 18F-fluorocholine ([18F]FCH) positron emission tomography/computed tomography (PET/CT) performed in prostate cancer patients. Material and methods: A retrospective analysis was performed on a group of 1345 prostate cancer patients, who underwent [18F]FCH PET/CT study because of suspicion of recurrence (n = 937) or for initial staging (n = 408). Images were acquired after intravenous injection [18F]FCH with a mean activity of 200 ± 75 MBq (5.4 ± 2 mCi), from the top of the head to the half of the thigh. The confirmation of second primary cancer was obtained from the cancer registry. Results: Based on the [18F]FCH PET/CT scans, a second primary cancer was suspected in 89 patients (6.6%). Of these, a malignancy was histologically confirmed in 26 patients (29% of all suspected findings and 1.9% of the complete cohort). Lung cancer (including adenocarcinoma, neuroendocrine cancer) was diagnosed in 13 patients (50%) and hematologic neoplasm (including chronic lymphocytic leukemia, Hodgkin lymphoma, follicular lymphoma, and multiple myeloma) in 5 patients (19%). 18F-fluorocholine PET/CT also revealed esophageal cancer, mesothelioma, testicular, renal, bladder, and colorectal cancer inindividual patients, non-keratinizing squamous cell carcinoma (SCC) of the skin as well as head and neck SCC with unknown primary. Conclusion: We conclude that incidental detection of a second primary cancer in prostate cancer patients using [18F]FCH PET/CT is not very common and that lung cancer and hematologic malignancies are most frequently detected.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

positron emission tomography/computed tomography; prostate cancer; second primary cancer

About this article
Title

Detection of a second primary cancer in a 18F-fluorocholine PET/CT – multicentre retrospective analysis on a group of 1345 prostate cancer patients

Journal

Nuclear Medicine Review

Issue

Vol 25, No 1 (2022)

Article type

Research paper

Pages

25-30

Published online

2022-01-26

Page views

6329

Article views/downloads

876

DOI

10.5603/NMR.a2022.0006

Pubmed

35137934

Bibliographic record

Nucl. Med. Rev 2022;25(1):25-30.

Keywords

positron emission tomography/computed tomography
prostate cancer
second primary cancer

Authors

Paulina Cegla
Katarzyna Scibisz-Dziedzic
Kamila Witkowska
Anna Kubiak
Ewa Wierzchoslawska
Witold Kycler
Beata Chrapko
Rafał Czepczyński

References (30)
  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
    CrossRefPubMed
  2. Feller L, Lemmer J. New 'second primary' cancers. SADJ. 2012; 67(4): 175–178.
    PubMed
  3. Nielsen SF, Nordestgaard BG, Bojesen SE. Associations between first and second primary cancers: a population-based study. CMAJ. 2012; 184(1): E57–E69.
    CrossRefPubMed
  4. Vali R, Loidl W, Pirich C, et al. Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine. Am J Nucl Med Mol Imaging. 2015; 5(2): 96–108.
    PubMed
  5. Kwee SA, DeGrado TR, Talbot JN, et al. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med. 2007; 37(6): 420–428.
    CrossRefPubMed
  6. Beheshti M, Haroon A, Bomanji JB, et al. Fluorocholine PET/computed tomography: physiologic uptake, benign findings, and pitfalls. PET Clin. 2014; 9(3): 299–306.
    CrossRefPubMed
  7. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001; 28(2): 117–122.
    CrossRefPubMed
  8. Evangelista L, Cimitan M, Zattoni F, et al. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis. Scand J Urol. 2015; 49(5): 345–353.
    CrossRefPubMed
  9. Fanti S, Minozzi S, Castellucci P, et al. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016; 43(1): 55–69.
    CrossRefPubMed
  10. Picchio M, Messa C, Landoni C, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol. 2003; 169(4): 1337–1340.
    CrossRefPubMed
  11. Gauvin S, Rompré-Brodeur A, Chaussé G, et al. F-fluorocholine positron emission tomography-computed tomography (F-FCH PET/CT) for staging of high-risk prostate cancer patients. Can Urol Assoc J. 2019; 13(4): 84–91.
    CrossRefPubMed
  12. Warren S, Gates O. Multiple primary malignant tumors: A survey of the literature and statistical study. Am J Cancer. 1932; 16: 1358–1414.
  13. Chun-Sing W, Nan-Jie G, Yiu-Ching C. Prevalence of synchronous second primary malignancy: identification using whole body PET/CT imaging. Clin Imaging. 2014; 38(2): 179–186.
    CrossRefPubMed
  14. Garcheva M, Zlatareva D, Gocheva L. Positron emission tomography combined with computed tomography for diagnosis of synchronous tumors. Klin Onkol. 2014; 27(4): 283–286.
    CrossRefPubMed
  15. Moletta L, Bissoli S, Fantin A, et al. PET/CT incidental detection of second tumor in patients investigated for pancreatic neoplasms. BMC Cancer. 2018; 18(1): 531.
    CrossRefPubMed
  16. Pang L, Liu G, Shi H, et al. Nineteen cases with synchronous multiple primary cancers studied by 18 F-FDG PET/CT. Hell J Nucl Med. 2017; 20(1): 36–40.
    CrossRefPubMed
  17. Gunes BY, Akbayır O, Demirci E, et al. Clinical, pathological and (18)F-FDG PET/CT findings in synchronous primary vaginal and endometrial cancers. Hell J Nucl Med. 2016; 19(2): 170–172.
    CrossRefPubMed
  18. Płachta M, Cholewiński W, Burchardt E, et al. Strategy and early results of treatment of advanced cervical cancer patients with synchronous cancers observed in PET-CT imaging. Ginekol Pol. 2017; 88(9): 475–480.
    CrossRefPubMed
  19. Strobel K, Haerle SK, Stoeckli SJ, et al. Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2009; 36(6): 919–927.
    CrossRefPubMed
  20. Miyazaki T, Sohda M, Higuchi T, et al. Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer. Anticancer Res. 2014; 34(1): 283–287.
    PubMed
  21. Amer MH. Multiple neoplasms, single primaries, and patient survival. Cancer Manag Res. 2014; 6: 119–134.
    CrossRefPubMed
  22. How Kit N, Dugué AE, Sevin E, et al. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy. Nucl Med Commun. 2016; 37(4): 348–355.
    CrossRefPubMed
  23. García JR, Ponce A, Canales M, et al. [Detection of second tumors in 11C-choline PET/CT studies performed due to biochemical recurrence of prostate cancer]. Rev Esp Med Nucl Imagen Mol. 2014; 33(1): 28–31.
    CrossRefPubMed
  24. Sollini M, Pasqualetti F, Perri M, et al. Detection of a second malignancy in prostate cancer patients by using [(18)F]Choline PET/CT: a case series. Cancer Imaging. 2016; 16(1): 27.
    CrossRefPubMed
  25. Buroni FE, Persico MG, Lodola L, et al. Malignant Lymphoma Imaged by 18F-Fluoro-Choline PET-CT in a Patient with Prostate Cancer: a Case Report and Review of Literatureostate Cancer: A Case Report and Review of the Literature. STJ Cancer. 2017; 1(1002).
  26. Tuscano C, Russi EG, Al Sayyad S, et al. An Incidental Finding of Mucinous Colon Cancer by (18)F-Choline PET/CT Determining a Change in Clinical Management of a Patient with Recurrent Prostate Adenocarcinoma. Case Rep Oncol Med. 2014; 2014: 297031.
    CrossRefPubMed
  27. Hodolic M, Huchet V, Balogova S, et al. Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiol Oncol. 2014; 48(3): 228–234.
    CrossRefPubMed
  28. Calabria F, Chiaravalloti A, Cicciò C, et al. PET/CT with 18 F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18 F-choline PET/CT bio-distribution and pitfalls. A southern Italian experience. Nucl Med Biol. 2017; 51: 40–54.
    CrossRefPubMed
  29. Pieterman RM, Que TH, Elsinga PH, et al. Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med. 2002; 43(2): 167–172.
    PubMed
  30. Giovacchini G, Giovannini E, Leoncini R, et al. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. Eur J Nucl Med Mol Imaging. 2017; 44(10): 1751–1776.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl